IKENA ONCOLOGY INC (IKNA) Forecast, Price Target & Analyst Ratings
NASDAQ:IKNA • US45175G1085
1.43 USD
+0.06 (+4.38%)
At close: Jul 25, 2025
1.46 USD
+0.03 (+2.1%)
After Hours: 7/25/2025, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IKENA ONCOLOGY INC (IKNA).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateNov 5, 2025
PeriodQ3 / 2025
EPS Estimate-$1.59
Revenue Estimate
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $1.43 to mean target of N/A, Based on 8 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
-33.33%
3 Months
-33.33%
Price Target Summary
The average price target has been revised downward by 33.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
IKNA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IKNA.
In the previous month the buy percentage consensus was at a similar level.
IKNA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-07-25 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-29 | Wedbush | Downgrade | Outperform -> Neutral |
| 2024-05-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-14 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-01-19 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-01-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-22 | Wedbush | Initiate | Outperform |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-16 | Credit Suisse | Reiterate | Outperform -> Outperform |
| 2023-03-17 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-15 | Credit Suisse | Maintains | Outperform |
| 2022-11-29 | Credit Suisse | Maintains | Outperform |
| 2022-11-29 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-08 | Credit Suisse | Maintains | Outperform |
| 2022-05-13 | Credit Suisse | Maintains | Outperform |
| 2022-04-13 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-23 | HC Wainwright & Co. | Initiate | Buy |
| 2021-08-13 | Credit Suisse | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateNov 5, 2025
PeriodQ3 / 2025
EPS Estimate-$1.59
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-657.71%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-1,100.00%
EPS (3 Months)
-1,100.00%
Next Earnings Summary
IKNA is expected to report earnings on 11/5/2025. The consensus EPS estimate for the next earnings is -1.59 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 30.99M 237.21% | 15.62M -49.60% | 9.16M -41.36% | -100.00% | 59.16M | 95.88M 62.07% | 122.4M 27.66% | 149.94M 22.50% | |||||
| EBITDA YoY % growth | -33.6M 24.02% | -70.15M -108.78% | -74.397M -6.05% | -90.803M 27.33% | -90.787M -67.93% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -34.14M 23.32% | -70.9M -107.67% | -75.417M -6.37% | -54.57M 27.66% | -33.489M 38.61% | -42.531M -27.00% | -59.006M -38.74% | -49.164M 16.68% | -25.092M 48.96% | 306K 101.22% | 16.218M 5,200.00% | 31.62M 94.97% | |
| Operating Margin | -110.16% | -453.91% | -823.33% | N/A | N/A | N/A | N/A | N/A | -42.41% | 0.32% | 13.25% | 21.09% | |
| EPS YoY % growth | -3.20 | -1.92 40.00% | -1.70 11.46% | -1.01 40.59% | -0.59 41.43% | -0.63 -6.90% | -0.76 -20.16% | -0.83 -8.72% | -0.01 98.77% | 0.40 4,000.00% | 0.71 79.49% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.59 -657.71% | -1.77 -834.11% | -0.20 90.56% | -0.29 60.33% | -0.29 82.05% | -0.31 82.76% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.386M 27.68% | -9.082M 25.40% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
7.65%
EPS Next 5 Year
14.75%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
IKENA ONCOLOGY INC / IKNA Forecast FAQ
When does IKENA ONCOLOGY INC (IKNA) report earnings?
IKENA ONCOLOGY INC (IKNA) will report earnings on 2025-11-05, before the market open.
Can you provide the consensus estimates for IKENA ONCOLOGY INC next earnings?
The consensus EPS estimate for the next earnings of IKENA ONCOLOGY INC (IKNA) is -1.59 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for IKENA ONCOLOGY INC stock?
The consensus rating for IKENA ONCOLOGY INC (IKNA) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.